Treatment‐associated phenotype switching between psoriasis and atopic dermatitis
Journal of the European Academy of Dermatology and Venereology · 2026-11 · 40 (11) · 1831-1839
DOI: 10.1111/jdv.70503 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 14.05.2026. Verfasst von Tiago Torres und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Centro Académico Clínico ICBAS/Santo António, Porto, Portugal. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Psoriasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Psoriasis and atopic dermatitis (AD) are traditionally viewed as distinct inflammatory skin diseases driven by type 17 and type 2 immune pathways, respectively. Increasing use of targeted therapies has revealed a treatment‐associated phenotype switch between these conditions, the so‐called ‘flip‐flop’ phenomenon, characterized by sustained emergence of eczematous features in patients treated for psoriasis or psoriasiform disease in those treated for AD. Robust real‐world data on this entity remain limited.
Objectives
To characterize treatment‐associated phenotype switching between psoriasis and AD in a large real‐world cohort, focusing on clinical features, implicated therapies, management strategies and outcomes.
Methods
We conducted a retrospective, multicentre, multinational observational study across 17 dermatology centres in six countries. Patients with psoriasis or AD who developed a clinician‐defined, persistent phenotype switch temporally associated with systemic or biologic therapy and requiring treatment modification were included. Demographic, clinical, therapeutic and outcome data were collected and analysed descriptively.
Results
A total of 148 patients were included: 101 (68.2%) developed eczematous features while treated for psoriasis (PsO → eczematous), and 47 (31.8%) developed psoriasiform disease while treated for AD (AD → psoriasiform). PsO → eczematous patients were older and had more cardiometabolic comorbidities, whereas atopic comorbidities were more frequent in the AD → psoriasiform group. PsO → eczematous switches occurred mainly under interleukin (IL)‐17 and IL‐23 inhibitors, while AD → psoriasiform switches occurred exclusively during biologic therapies targeting type 2 inflammation, predominantly dupilumab. Treatment was modified in all patients. Janus kinase (JAK) inhibitors were the most frequently used strategy in both switch directions, particularly in PsO → eczematous cases. Marked clinical improvement was observed across phenotypes following therapeutic adjustment.
Conclusions
Treatment‐associated phenotype switching between psoriasis and AD is a reproducible, bidirectional and clinically relevant real‐world phenomenon reflecting immune plasticity rather than paradoxical disease induction. Recognition of this entity is essential to guide appropriate therapeutic adaptation, with JAK inhibitors emerging as a commonly effective management option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Centro Académico Clínico ICBAS/Santo António, Porto, Portugal.
- Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal.
- Dermatology Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Milan, Italy.
- Unit of Dermatology, University of Campania Luigi Vanvitelli, Naples, Italy.
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
ORCID-Profile: Tiago Torres, Anna Balato, Paolo Gisondi, Julia-Tatjana Maul, Jose Manuel Carrascosa, Francisco José Navarro-Triviño, Esteban Dauden, Mar Llamas-Velasco, Ron Vender, Angelo Marzano, Luis Puig
Zitieren
APA
Torres, T., Valenti, M., Balato, A., Megna, M., Gisondi, P., Prajapati, V., Piaserico, S., Maul, J. T., Maul, L. V., Carrascosa, J. M., Navarro-Triviño, F. J., Lazaridou, E., Ferreira, C., Tartaglia, J., Ciolfi, C., Daponte, A. I., Brizzi, E. V. D., Napolitano, M., Guerra, B. L., …, & Puig, L. (2026). Treatment‐associated phenotype switching between psoriasis and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology, 40(11), 1831-1839. https://doi.org/10.1111/jdv.70503
Vancouver
Torres T, Valenti M, Balato A, Megna M, Gisondi P, Prajapati V, et al. Treatment‐associated phenotype switching between psoriasis and atopic dermatitis. Journal of the European Academy of Dermatology and Venereology. 2026;40(11):1831-1839. doi:10.1111/jdv.70503
BibTeX
@article{Torres2026,
author = {Torres, Tiago and Valenti, Mario and Balato, Anna and Megna, Matteo and Gisondi, Paolo and Prajapati, Vimal and Piaserico, Stefano and Maul, Julia-Tatjana and Maul, Lara Valeska and Carrascosa, Jose Manuel and Navarro-Triviño, Francisco José and Lazaridou, Elizabeth and Ferreira, César and Tartaglia, Jacopo and Ciolfi, Christian and Daponte, Athina-Ioanna and Brizzi, Eugenia Veronica Di and Napolitano, Maddalena and Guerra, Barbara Leal and Munera-Campos, Monica and Sood, Siddhartha and Ferruci, Silvia and Prignano, Francesca and Dauden, Esteban and Llamas-Velasco, Mar and Vender, Ron and Yeung, Jensen and Marzano, Angelo and Puig, Luis},
title = {Treatment‐associated phenotype switching between psoriasis and atopic dermatitis},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
volume = {40},
number = {11},
pages = {1831--1839},
doi = {10.1111/jdv.70503}
}
EUVIMED